# Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.

> **NCT00151788** · PHASE2,PHASE3 · TERMINATED · sponsor: **Daiichi Sankyo** · enrollment: 796 (—)

## Conditions studied

- Atherosclerosis
- Heterozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** Pactimibe sulfate

## Key facts

- **NCT ID:** NCT00151788
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-02
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 796 (—)
- **Last updated:** 2012-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151788, "Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00151788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*